69
Views
6
CrossRef citations to date
0
Altmetric
Clinical Focus: Diabetes

Linagliptin: A New DPP-4 Inhibitor for the Treatment of Type 2 Diabetes Mellitus

, MD, PhD
Pages 46-53 | Published online: 13 Mar 2015
 

Abstract

Incretin-based therapies constitute a relatively new pharmacological approach to the treatment of type 2 diabetes mellitus. As reflected in the rapidly growing body of literature and the number of glucagon-like peptide-1 and dipeptidyl peptidase-4 inhibitor (DPP-4) compounds that are either approved or in development, there is considerable interest in treatments that target the incretin axis. Linagliptin is a recently approved DPP-4 inhibitor with unique pharmacological properties, including very high affinity for the DPP-4 enzyme, postdose DPP-4 inhibition > 80% after 24 hours, and a primarily fecal route of elimination. Phase 3 clinical trials on > 4000 patients have demonstrated the efficacy of linagliptin as monotherapy or in combination with other antidiabetic agents. Treatment with linagliptin reduced glycated hemoglobin by 0.6% to 0.8%, with a safety profile comparable with placebo. This article provides a review of linagliptin clinical data for primary care physicians treating patients with type 2 diabetes mellitus.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.